Inside informationEnglish
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 20/10/2025, 13:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 113893_20251020